Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485896 | 1.00 | MAPK1 (0.64) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL5804418 | 0.93 | TSHR (0.79) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL10531067 | 0.93 | MAPK1 (0.56) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL306375 | 0.85 | ALDH1A1 (0.64) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL29580152 | 0.85 | ALDH1A1 (0.64) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL2655681 | 0.85 | TDP1 (0.56) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL1524058 | 0.80 | MAPK1 (0.72) | MAPK1TDP1TSHRALDH1A1POLB | |
| SCHEMBL18547550 | 0.79 | VCAM1 (0.57) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL27542809 | 0.79 | VCAM1 (0.62) | MAPK1TDP1TSHRATMALDH1A1 | |
| SCHEMBL11516745 | 0.78 | MAPK1 (0.69) | MAPK1TDP1TSHRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1031 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106117067-B | A kind of method that diazotising prepares 3,5 difluoro, 4 chloronitrobenzene | 江苏扬农化工集团有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-106905161-A | A kind of synthetic method of the nitrobenzoic acid of 2 chlorine, 4 fluorine 5 | 常州沃腾化工科技有限公司 | 2017-06-30 | — | — | CN | claimed |
| CN-1162393-C | Chemical synthesis process of 4-chloro-2-fluoro nitrobenzene | 浙江工业大学 | 2004-08-18 | — | — | CN | claimed |
| CN-1398846-A | Chemical synthesis process of 4-chloro-2-fluoro nitrobenzene | UNIV ZHEJIANG POLYTECHNIC (CN) | 2003-02-26 | — | — | CN | claimed |
| JP-3109360-A | — | — | None | — | — | JP | disclosed |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-12521368-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-4229365-A | Manufacture of substituted fluorobenzenes | BASF AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-4226811-A | Preparation of substituted fluorobenzenes | BASF AKTIENGESELLSCHAFT (DE) | 1980-10-07 | — | — | US | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4164517-A | REACTING A CHLORONITROBENZENE WITH POTASSIUM FLUORIDE IN SULFOLANE | I.S.C. CHEMICALS LIMITED (GB) | 1979-08-14 | — | — | US | disclosed |
| EP-0003344-A1 | Process for the preparation of fluor benzenes | BASF Aktiengesellschaft (DE) | 1979-08-08 | — | — | EP | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | CBX2, CBX3, CBX6 | MAPK1 2699/4885TDP1 2682/4885TSHR 4302/4885 |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, TNFRSF9 | MAPK1 729/4885TDP1 4065/4885TSHR 396/4885 |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, CD40 | MAPK1 744/4885TDP1 501/4885TSHR 1074/4885 |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | MAPK1 1136/4885TDP1 1565/4885TSHR 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.